» Authors » Andrea Campana

Andrea Campana

Explore the profile of Andrea Campana including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 63
Citations 1264
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Staccioli S, Mariani R, Bompard S, Olivini N, Fanfoni C, Mirra G, et al.
Pediatr Neurol . 2024 Nov; 162():28-31. PMID: 39531962
Background: Alice in Wonderland syndrome (AIWS) is a disorienting neurological condition that affects human perception to the senses of vision, hearing, touch, and sensation and the phenomenon of time. Herein...
2.
Scutari R, Fox V, Fini V, Granaglia A, Vittucci A, Smarrazzo A, et al.
Sci Rep . 2024 Mar; 14(1):5325. PMID: 38438451
Since its emergence, SARS-CoV-2 Omicron clade has shown a marked degree of variability and different clinical presentation compared with previous clades. Here we demonstrate that at least four Omicron lineages...
3.
Piazzesi A, Pane S, Del Chierico F, Romani L, Campana A, Palma P, et al.
Front Cell Infect Microbiol . 2024 Feb; 14:1335450. PMID: 38318164
Introduction: Since the beginning of the SARS-CoV-2 pandemic in early 2020, it has been apparent that children were partially protected from both infection and the more severe forms of the...
4.
Marzano V, Mortera S, Marangelo C, Piazzesi A, Rapisarda F, Pane S, et al.
Front Cell Infect Microbiol . 2024 Jan; 13:1327889. PMID: 38188629
Introduction: The gut microbiota (GM) play a significant role in the infectivity and severity of COVID-19 infection. However, the available literature primarily focuses on adult patients and it is known...
5.
Licciardi F, Covizzi C, Dellepiane M, Olivini N, Mastrolia M, Lo Vecchio A, et al.
Front Pediatr . 2023 Sep; 11:1137051. PMID: 37675397
Background: The treatment of multisystem inflammatory syndrome in children unresponsive to first-line therapies (IVIG and/or steroids) is challenging. The effectiveness of IL-1 receptor antagonist, anakinra, is debated. Patients And Methods:...
6.
Scarselli V, Calderoni D, Terrinoni A, Davico C, Pruccoli G, Denina M, et al.
J Clin Med . 2023 Jun; 12(12). PMID: 37373611
Aim: Concerns have been raised about possible neuropsychiatric sequelae of COVID-19. The objective of this study was to examine the plausibility of long-term mental health consequences of COVID-19 by assessing...
7.
Giuliano M, Tiple D, Agostoni P, Armocida B, Biardi L, Bonfigli A, et al.
Front Public Health . 2023 May; 11:1122141. PMID: 37151592
A significant number of people, following acute SARS-CoV-2 infection, report persistent symptoms or new symptoms that are sustained over time, often affecting different body systems. This condition, commonly referred to...
8.
Alteri C, Fox V, Scutari R, Burastero G, Volpi S, Faltoni M, et al.
Commun Biol . 2022 Dec; 5(1):1376. PMID: 36522489
Little is known about SARS-CoV-2 evolution under Molnupiravir and Paxlovid, the only antivirals approved for COVID-19 treatment. By investigating SARS-CoV-2 variability in 8 Molnupiravir-treated, 7 Paxlovid-treated and 5 drug-naïve individuals...
9.
Dona D, Montagnani C, Di Chiara C, Venturini E, Galli L, Lo Vecchio A, et al.
Viruses . 2022 Oct; 14(10). PMID: 36298812
Compared to adults, severe or fatal COVID-19 disease is much less common in children. However, a higher risk for progression has been reported in infants. Different pediatric COVID-19 severity scores...
10.
Cantarutti N, Battista V, Stagnaro N, Labate M, Cicenia M, Campisi M, et al.
Biology (Basel) . 2022 Oct; 11(10). PMID: 36290378
MIS-C is a multisystem inflammatory syndrome that is characterized by multi-organ failure and cardiac involvement. The aim of this study was to describe the long-term cardiovascular outcome in a cohort...